Weekly mobile phone text messaging may help patients with human immunodeficiency virus adhere to antiretroviral therapy that is often associated with difficult side effects, according to a study published online March 14 in the Cochrane Database of Systematic Reviews.
Weekly mobile phone text messaging may help patients with human immunodeficiency virus (HIV) adhere to antiretroviral therapy (ART) that is often associated with difficult side effects, according to a study published online March 14 in the Cochrane Database of Systematic Reviews.
Tara Horvath of Global Health Sciences at the University of California, San Francisco, and colleagues noted that ART adherence is important for survival, to prevent drug resistance requiring a more expensive second-line regimen, and for suppressing viral load, which significantly reduces the likelihood of transmission.
High-quality evidence suggests that weekly text messages may enhance ART adherence, so investigators reviewed 2 randomized controlled trials from Kenya including a total of 966 adult patients with HIV. One trial compared short weekly text messages against standard care. The other trial compared short-daily, long-daily, short-weekly, and long-weekly messages against standard care.
Patients receiving standard care in each study received a mobile phone but did not receive any study-related mobile communication.
Those assigned to intervention in the first study were sent brief text messages, such as, “How are you?”, and were expected to respond within 48 hours. In the second study, patients assigned to intervention received daily or weekly short text messages, such as, “This is your reminder,” or daily or weekly long text messages, such as, “This is your reminder. Be strong and courageous. We care about you.”
At 48-52 weeks, combined data from both trials demonstrated that any text messaging was associated with greater ART adherence, weekly texts of any length were associated with adherence, and short weekly text messages were associated with adherence. In the first trial, short weekly texts were also associated with viral load suppression at 52 weeks.
Based on the quality of the evidence, the researchers concluded, “Policy-makers should consider funding programs proposing to provide weekly mobile phone text-messaging as a means for promoting adherence to antiretroviral therapy. Clinics and hospitals should consider implementing such programs.”
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More